However, while the cardiovascular benefits of SGLT2 inhibitors in general populations with T2DM or HF are well-established [4], their role in cancer patients with T2DM remains poorly characterized, despite compelling biological plausibility and growing clinical need. The gene discussed is SLC5A2; the disease is hydrops fetalis.